NeXtGen Biologics
About this raise: NeXtGen Biologics, with a valuation of $40 million, is raising funds on Republic. The company has developed a patented and FDA-cleared wound-care technology involving the extracellular matrix (ECM). The technology captures the regenerative power of the axolotl and has potential applications in general surgery, wounds and burns, plastic surgery, cardiovascular diseases, ophthalmology, and gastrointestinal diseases. The first product of NeXtGen Biologics, NEOMATRIX, is the first ECM product derived from the axolotl and available to physicians and patients. Jonelle Toothman founded NeXtGen Biologics in April 2014. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $5 million. The campaign proceeds will be used for the soft and full-scale launch of NEOMATRIX.
Investment Overview
Invested : $241,610
Deal Terms
Total Commitments ($USD)
- Platform
- Republic
- Start Date
- 09/02/2022
- Close Date
- 02/28/2023
$25,000
$5,000,000
$250
SAFE
Series A
RegCF
$40,000,000
0%
Company & Team
Company
- Year Founded
- 2014
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2C
- Margin
- High
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $13,998,288
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 02/28/2023 | Republic | $40,000,000 | $241,610 | SAFE | Funded | RegCF |